Interleukin-10 pathway-mediated regulatory T cell induction (IL-10 pathway (for the pathway); IL-10 (for the cytokine))

The "Immune system modulation via regulatory T cell induction (IL‑10 pathway)" refers to a key immunoregulatory mechanism where the cytokine interleukin‑10 promotes both the differentiation and function of regulatory CD4+ T lymphocytes—especially Foxp3+ natural and induced regulatory T cells. This process is essential for maintaining immune homeostasis by limiting excessive inflammatory responses, preventing tissue damage during infection, and promoting tolerance to self-antigens. Interleukin‑10 acts through its receptor complex—composed primarily of IL‑10RA and IL‑10RB subunits—to activate intracellular JAK1/TYK2/STAT3 signaling cascades. This leads to transcriptional changes that suppress pro-inflammatory gene expression in antigen-presenting cells such as dendritic cells and macrophages while also directly supporting the expansion, stability, and suppressive function of both natural thymic-derived ("nTreg") and peripherally-induced ("iTreg") Foxp3+ regulatory populations[1][2][4]. The presence of additional factors like transforming growth factor beta (TGFβ) can synergize with IL‑10 to further enhance iTreg generation from naïve CD4+ precursors[3]. Therapeutically targeting this axis is considered promising for treating autoimmune diseases, allergies, chronic inflammatory conditions, transplant rejection risk reduction—and potentially some infectious diseases—by restoring balance between effector immunity and regulation. However, safety concerns include heightened risk for infections due to broad suppression of protective immune responses as well as possible negative effects on tumor surveillance if used chronically or systemically. In summary: The "Immune system modulation via regulatory T cell induction (IL-10 pathway)" describes a validated therapeutic target centered on harnessing interleukin-10’s ability to induce potent immunoregulatory mechanisms through expansion/functionality enhancement of Foxp3+ regulatory CD4+ lymphocytes via defined molecular pathways involving STAT family transcription factors.[1][2][3][5]

Other names

IL-10 signalingInterleukin-10 signalingRegulatory T cell induction via IL-10Foxp3+ regulatory T cell induction (IL-10 mediated)

Drugs or biologics targeting this molecule/pathway act by enhancing or mimicking IL‑10 activity to promote immune tolerance, suppress effector T cell responses, inhibit antigen-presenting cell activation, and induce/expand functional regulatory T cells[3][5].